Page last updated: 2024-08-21

quinazolines and Central Nervous System Diseases

quinazolines has been researched along with Central Nervous System Diseases in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (25.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ardecky, RJ; Bai, Y; Barak, LS; Caron, MG; Chung, TDY; Falter, B; Hedrick, MP; Hershberger, P; Jackson, MR; Maloney, P; Peddibhotla, S; Pinkerton, AB; Slosky, LM; Smith, LH; Yamamoto, F	1
Dhulap, S; Gavaraskar, K; Hirwani, RR	1
Akazawa, Y; Imamura, F; Kumagai, T; Nishino, K; Okyuama, T; Uchida, J	1
Allan, R; Bleicher, M	1

Reviews

1 review(s) available for quinazolines and Central Nervous System Diseases

Article	Year
Therapeutic and cosmetic applications of Evodiamine and its derivatives--A patent review. Fitoterapia, 2015, Volume: 106 Topics: Alkaloids; Animals; Autoimmune Diseases; Cell Line, Tumor; Central Nervous System Diseases; Cosmetics; Evodia; Fruit; Humans; Inflammation; Metabolic Diseases; Molecular Structure; Neoplasms; Patents as Topic; Quinazolines	2015

Trials

1 trial(s) available for quinazolines and Central Nervous System Diseases

Article	Year
Biarison in the treatment of degenerative joint diseases: comparison with indomethacin and placebo. The Journal of international medical research, 1977, Volume: 5, Issue:4 Topics: Adult; Aged; Anti-Inflammatory Agents; Central Nervous System Diseases; Double-Blind Method; Drug Tolerance; Female; Humans; Indomethacin; Male; Middle Aged; Osteoarthritis; Placebos; Quinazolines	1977

Other Studies

2 other study(ies) available for quinazolines and Central Nervous System Diseases

Article	Year
Discovery of β-Arrestin Biased, Orally Bioavailable, and CNS Penetrant Neurotensin Receptor 1 (NTR1) Allosteric Modulators. Journal of medicinal chemistry, 2019, 09-12, Volume: 62, Issue:17 Topics: Administration, Oral; Allosteric Regulation; Animals; beta-Arrestins; Biological Availability; Central Nervous System Diseases; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Drug Discovery; Female; Locomotion; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Molecular Structure; Quinazolines; Rats; Receptors, Neurotensin; Structure-Activity Relationship	2019
Subacute transient encephalopathy induced by erlotinib. Oncology research, 2011, Volume: 19, Issue:8-9 Topics: Aged; Carcinoma, Non-Small-Cell Lung; Central Nervous System Diseases; Confusion; Erlotinib Hydrochloride; Female; Humans; Irritable Mood; Lethargy; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Seizures; Unconsciousness; Urinary Incontinence	2011

Article

Year

Discovery of β-Arrestin Biased, Orally Bioavailable, and CNS Penetrant Neurotensin Receptor 1 (NTR1) Allosteric Modulators.

Journal of medicinal chemistry, 2019, 09-12, Volume: 62, Issue:17

Topics: Administration, Oral; Allosteric Regulation; Animals; beta-Arrestins; Biological Availability; Central Nervous System Diseases; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Drug Discovery; Female; Locomotion; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Molecular Structure; Quinazolines; Rats; Receptors, Neurotensin; Structure-Activity Relationship

2019

Subacute transient encephalopathy induced by erlotinib.

Oncology research, 2011, Volume: 19, Issue:8-9

Topics: Aged; Carcinoma, Non-Small-Cell Lung; Central Nervous System Diseases; Confusion; Erlotinib Hydrochloride; Female; Humans; Irritable Mood; Lethargy; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Seizures; Unconsciousness; Urinary Incontinence

2011